Ankylosing Spondylitis

Featured Article
Treatment Produces Clinically Meaningful Response in Active Ankylosing Spondylitis
“Currently, the unmet need for treatment options is high in patients with ankylosing spondylitis, including a need for effective oral treatment options following NSAIDs and a need for additional mechanisms of action,” researchers wrote.
As a Second Biologic for Spondyloarthritis, Treatment Shows High Retention Rates
“Because persistence with the same anti-TNF drug in second-line treatment decreases the overall disease-associated costs compared with non-persistence, this aspect … merits consideration by…
When TNFi Doses are Reduced, Ankylosing Spondylitis Medical Costs Decrease
“The cost of AS-related total medical care significantly increased medical cost savings from 24.85% to 35.52% following TNFi dose reduction,” researchers concluded.

Newsfeed

Treatment Produces Clinically Meaningful Response in Active Ankylosing Spondylitis
As a Second Biologic for Spondyloarthritis, Treatment Shows High Retention Rates
When TNFi Doses are Reduced, Ankylosing Spondylitis Medical Costs Decrease
Biologic Strategies for Ankylosing Spondylitis Not Cost-Effective at Common Threshold
Switching or Discontinuing Ankylosing Spondylitis Biologics Raises Medical Costs
Understanding the Link Between bDMARD Initiation, Switching With Mood Disorders
Disease Activity in Axial Spondylarthritis Patients Linked With Current State of Health Care Stress
Ankylosing Spondylitis Improvement Sustained After 5 Years of Secukinumab Treatment
View More
Back to Top